Quantitative estimation of drugs for erectile dysfunction and benign prostatic hyperplasia by high performance liquid chromatography: a review

This review article explores the critical application of High-Performance Liquid Chromatography (HPLC) in analyzing medications for Erectile Dysfunction (ED) and Benign Prostatic Hyperplasia (BPH). HPLC is essential for the precise measurement of these drugs, whether assessed individually or within combination therapies. The review thoroughly examines various HPLC methodologies, encompassing both single-drug and simultaneous analysis techniques. It addresses the optimization of HPLC conditions and validation practices necessary for achieving reliable results. Key challenges in HPLC analysis are highlighted, including sensitivity issues and the need for specific adjustments in analytical procedures. The article discusses the influence of factors such as column types, mobile phases, and detection methods on HPLC performance. It offers detailed insights into optimizing parameters to enhance resolution and accuracy, providing practical guidance for researchers working with ED and BPH drugs. Moreover, the review outlines best practices for validating HPLC methods according to regulatory standards, which are crucial for maintaining the quality and reproducibility of analytical results. It also identifies potential areas for improvement, including enhancing method sensitivity and reducing analysis time. By emphasizing the importance of HPLC in maintaining high analytical standards for ED and BPH drug analysis, this review serves as a valuable resource for researchers, clinicians, and pharmaceutical companies, ultimately aiming to enhance drug management and improve patient outcomes through better analytical practices and innovative approaches.